ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0818

Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis

Miriam Retuerto1, Elisa Trujillo2, Cristina Valero3, Cruz Fernández-Espartero4, Christian Soleto-Kharkovskaya5, Andrea García Valle6, Elena Aurrecoechea7, Marta Garijo8, Javier Loricera9 and Jose Luis Pablos10, 1Hospital universitario 12 de octubre, Madrid, Spain, 2Hospital universitario de Canarias, Santa Cruz de Tenerife, Spain, 3Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, 4H. Mostoles, Madrid, Spain, 5Gregorio Marañón University Hospital, Madrid, 6H. Palencia, Palencia, Spain, 7Hospital de Sierrallana, Torrelavega, Spain, 8Hospital de Sagunto, Valencia, Spain, 9Hospital Universitario Marqués de Valdecilla, Santander, Spain, 10Hospital 12 de Octubre, Madrid, Spain

Meeting: ACR Convergence 2020

Keywords: rheumatoid arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Saturday, November 7, 2020

Session Title: RA – Treatments Poster II: Comparative Effectiveness, Biosimilars, Adherence & the Real World

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Different jakinibs have shown efficacy in rheumatoid arthritis (RA) but in an important proportion of patients, insufficient response leads to therapy withdrawal. The different jakinibs show variable selectivity for the four Jak isoforms (Jak1,2,3 y Tyk2) but there are no clinical trials analyzing the response to a jakinib after the suspension of another jakinib and therefore, observational data may be useful in this regard. The aim of this study is to describe efficacy and safety of the second jakinib in patients with suspension of the first due to failure or side effects.

Methods: Spanish observational multicentric study. Data were retrospectively obtained from medical records of 31 patients with RA sequentially treated with baricitinib or tofacitinib in any order.

Results: We identified 31 patients with RA, median age 62 years (IQR 51-67), 80.6% female (Table 1). Rheumatoid factor and anti-CCP was positive in 80.6% and 71% of the patients . Most of the patients (87%) had received previously treatment with bDMARD, median number of previous bDMARDs 4 (IQR 2-5). Half of the patients received Tofacitinib first, and the other half Baricitinib as the first Jakinib. Median survival for the first Jakinib was 5 months (IQR 3-8) and the reason for withdrawal was inefficacy in 19 cases (61.3%) and adverse effects in 12 (38.7%). Median DAS28CPR in the beginning of the second jakinib was 5.3 (IQR 5-5.9), 9 patients were treated in monotherapy and 26 used glucocorticoids.

9 patients discontinued the second Jakinib, in all of them the reason was inefficacy. The treatment suspension rate was similar among patients discontinuing the first Jakinib for inefficacy (5/19, 26.3%) or for adverse effects (3/12; 25%). Median follow-up of patients who didn’t discontinue the second Jakinib was 19.5 (IQR 12-24) months. Disease activity data along this follow-up are depicted in Figure 1 and 2.

Conclusion: Our data show that therapy with a second jakinib is a safe and efficacious option after discontinuation of the first jakinib due to either inefficacy or side effects. The response rate to the second jakinib is similar in patients with inefficacy or side effects which suggests that failure to the first does not reduce the chance of response to the second.

Acknowledgements: M. Retuerto was recipient of a training grant from Sociedad Española de Reumatología (SER).

Table 1. Characteristics of 31 patients with RA treated sequentially with two jakinibs.

Figure 1. Second jakinib treatment results during the follow-up period (median).

Figure 2. Second jakinib activity development.


Disclosure: M. Retuerto, None; E. Trujillo, None; C. Valero, None; C. Fernández-Espartero, None; C. Soleto-Kharkovskaya, None; A. García Valle, None; E. Aurrecoechea, None; M. Garijo, None; J. Loricera, None; J. Pablos, None.

To cite this abstract in AMA style:

Retuerto M, Trujillo E, Valero C, Fernández-Espartero C, Soleto-Kharkovskaya C, García Valle A, Aurrecoechea E, Garijo M, Loricera J, Pablos J. Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-safety-of-switching-jakinibs-in-rheumatoid-arthritis/. Accessed February 24, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-switching-jakinibs-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.